No headlines found.
IQVIA CFO Ron Bruehlman to Speak at Barclays Annual Global Healthcare Conference on March 13, 2024
Business Wire (Wed, 6-Mar 4:15 PM ET)
IQVIA Publishes its 2023 Environmental, Social and Governance Report
Business Wire (Mon, 26-Feb 8:00 AM ET)
Business Wire (Fri, 23-Feb 9:00 AM ET)
Business Wire (Wed, 21-Feb 4:15 PM ET)
IQVIA Reports Fourth-Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance
Business Wire (Wed, 14-Feb 7:00 AM ET)
Business Wire (Tue, 6-Feb 9:00 AM ET)
IQVIA to Announce Fourth-Quarter and Full-Year 2023 Results on February 14, 2024
Business Wire (Wed, 24-Jan 4:15 PM ET)
Business Wire (Wed, 17-Jan 6:00 AM ET)
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Iqvia Hldgs trades on the NYSE stock market under the symbol IQV.
As of March 28, 2024, IQV stock price declined to $251.97 with 42,366 million shares trading.
IQV has a beta of 1.51, meaning it tends to be more sensitive to market movements. IQV has a correlation of 0.46 to the broad based SPY ETF.
IQV has a market cap of $45.86 billion. This is considered a Large Cap stock.
Last quarter Iqvia Hldgs reported $4 billion in Revenue and $2.84 earnings per share. This beat revenue expectation by $78 million and exceeded earnings estimates by $.02.
In the last 3 years, IQV stock traded as high as $285.61 and as low as $165.75.
The top ETF exchange traded funds that IQV belongs to (by Net Assets): VTI, VOO, VO, SPY, IVV.
IQV has underperformed the market in the last year with a price return of +32.0% while the SPY ETF gained +33.8%. IQV has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +8.6% and -1.4%, respectively, while the SPY returned +10.2% and +1.8%, respectively.
IQV support price is $249.30 and resistance is $255.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IQV stock will trade within this expected range on the day.